Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02765854 · OUTCOME

Prevalence of NFKB2 Rearrangement in Relapsed/Refractory Multiple Myeloma Patients Screened in the Study.

Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement · Source last updated 2025-06-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
At baseline and month 12

What was measured

To determine the prevalence of NFKB2 rearrangement according to the type of previous therapies received in all patients screened in the study.

Groups in this outcome

Arm B (Ixazomib and Dexamethasone)

MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A. Dexamethasone: Given PO Ixazomib: Given PO

Arm C (Ixazomib, Dexamethasone, Lenalidomide)

MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21. Dexamethasone: Given PO Ixazomib: Given PO Lenalidomide: Given PO

Arm A (Ixazomib and Dexamethasone)

UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone. Dexamethasone: Given PO Ixazomib: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm B (Ixazomib and Dexamethasone)22
Arm C (Ixazomib, Dexamethasone, Lenalidomide)21
Arm A (Ixazomib and Dexamethasone)27

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm B (Ixazomib and Dexamethasone)22Not reportedNot reportedNot reportedNot reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)21Not reportedNot reportedNot reportedNot reported
Arm A (Ixazomib and Dexamethasone)0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        22
      2. group Id
        OG001
        value
        21
      3. group Id
        OG002
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      22
    2. group Id
      OG001
      value
      21
    3. group Id
      OG002
      value
      27
    units
    Participants
description
To determine the prevalence of NFKB2 rearrangement according to the type of previous therapies received in all patients screened in the study.
groups
  1. description
    MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A. Dexamethasone: Given PO Ixazomib: Given PO
    id
    OG000
    title
    Arm B (Ixazomib and Dexamethasone)
  2. description
    MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21. Dexamethasone: Given PO Ixazomib: Given PO Lenalidomide: Given PO
    id
    OG001
    title
    Arm C (Ixazomib, Dexamethasone, Lenalidomide)
  3. description
    UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone. Dexamethasone: Given PO Ixazomib: Given PO
    id
    OG002
    title
    Arm A (Ixazomib and Dexamethasone)
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
At baseline and month 12
title
Prevalence of NFKB2 Rearrangement in Relapsed/Refractory Multiple Myeloma Patients Screened in the Study.
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice